MANSFIELD – Covidien Plc said Tuesday its fiscal fourth-quarter profit dropped 86 percent because of charges related to a tax agreement for its former parent company, Tyco International Ltd., and other one-time expenses.
But Wall Street cheered the results, focusing on the company’s improved outlook for fiscal 2010 and growth in its medical devices division.
Rhode Island's Market Has Changed. Developers, Builders, Investors and Sellers Must Change With It.
By Emilio DiSpirito IV License Partner | Engel & Völkers Oceanside Leader | The DiSpirito…
Learn More
Covidien posted a profit of $56 million, or 11 cents a share, for the three months ended Sept. 25, down from a profit of $409 million, or 84 cents a share, a year earlier. Revenue was flat at $2.7 billion.
Excluding charges, Covidien said earnings rose to 72 cents from 68 cents last year. Analysts polled by Thomson Reuters had forecast earnings of 70 cents on $2.62 billion in sales.
Covidien said revenue increased 4 percent measured in constant currencies and if sales of discontinued painkiller oxycodone are excluded.
Sales in Covidien’s largest division, medical devices, rose 7 percent year over year. Pharmaceutical product sales fell 10 percent.
For the 2009 fiscal year that ended Sept. 25, Covidien reported net income of $907 million, or $1.79 per share, down 13 percent from $1.36 billion, or $2.70 per share, a year earlier. Excluding charges, profit totaled $1.43 billion, or $2.84 a share. Annual sales rose 3 percent to $10.68 billion.
Covidien said it expects revenue to increase by 6 percent to 9 percent in fiscal 2010 to between $11.32 billion and $11.64 billion, partly because the weaker U.S. dollar will make its products more competitive overseas.
The company had previously forecast sales growth of 4 percent to 7 percent, and analysts polled by Thomson Reuters prior to the new guidance’s release had forecast revenue of $10.78 billion in the fiscal year that ends next September.
“Strength in medical devices should help put industry volume and hospital inventory de-stocking concerns to rest,” Morgan Stanley analyst David Lewis said in a note to clients quoted by Reuters.
Covidien stock closed at $45.13 on Tuesday, up 2.4 percent from the previous day. The shares fell 0.8 percent to $44.76 at 11:37 a.m. Wednesday in New York Stock Exchange trading.
Additional information is available at covidien.com.
